Health · Medical Research · 3 hrs ago
South Korean biotech firms to present blood cancer research at ASH 2026
Several South Korean biotech companies will present blood cancer research at the American Society of Hematology’s annual meeting in New Orleans this December.
Curocell plans to share long-term follow-up data for its CAR-T treatment Limmcato, including outcomes tracked for up to 44.5 months.
Among patients who kept a complete response for at least six months, the reported three-year survival rate was 81.6%, and the rate without disease progression was 63.0%.
GC Cell will present early results from a phase 1a trial of cell therapy GCC2005; no dose-limiting toxicities or serious treatment-related side effects were reported, and some patients had complete responses that lasted.
LegoChem Biosciences plans to present preclinical results for its CD33-targeting drug LCB122A, while HLB Innovation’s US subsidiary will share interim phase 1 results for its CAR-T treatment SynKIR-310.
The findings are early-stage research, and the companies say they plan to continue clinical development, including a global phase 1 trial of LCB122A for patients with relapsed or refractory acute myeloid leukemia.
South Korean biotech firms plan to present blood cancer research at the American Society of Hematology’s 2026 annual meeting in New Orleans in December.
Curocell will present long-term follow-up data for its CAR-T therapy limkatto, including outcomes for patients who maintained a complete response for at least six months.
GC Cell will report Phase 1a results for its cell therapy GCC2005, including safety findings and early signs of anti-tumour activity.
LegoChem Biosciences will present preclinical findings for its CD33-targeting antibody-drug conjugate LCB122A and interim Phase 1 results for partner Ixaka Therapeutics’ IKS03.
HLB Innovation’s US subsidiary, Verismo Therapeutics, will present interim Phase 1 results for its blood cancer CAR-T therapy SynKIR-310.
- Who
- Curocell, GC Cell, LegoChem Biosciences and HLB Innovation’s US subsidiary Verismo Therapeutics.
- What
- They plan to present blood cancer treatment research. The presentations include clinical results and preclinical findings.
- When
- At ASH 2026, which is scheduled for December. The article was published on November 5, 2026.
- Where
- New Orleans, United States.
- Why
- Not stated
This story does not have two clearly opposing sides.
Yonhap reported that South Korean biotech firms planned to present research at ASH 2026.
ASH 2026 is scheduled to take place in New Orleans.
- Conference
- ASH 2026, New Orleans
- Curocell therapy
- Limkatto, a CAR-T treatment
- Curocell follow-up
- Up to 44.5 months
- GC Cell therapy
- GCC2005, Phase 1a results
- LegoChem candidate
- LCB122A, a CD33-targeting ADC
- Verismo candidate
- SynKIR-310, a blood cancer CAR-T therapy
1 source
What people are saying
These long-term follow-up data once again confirm limkatto’s efficacy and safety, and we will proceed with its domestic launch within the year as planned.
Based on the confirmed safety and initial clinical results, we will proceed with the ongoing Phase 1b trial as planned, establish the optimal dose and accelerate progress towards global clinical development.